Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

Hozzl · 2025-03-21T17:17:05Z

Explore the details of House Bill 1796 Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

3/21/2025, 5:17 PM

Summary of Bill HR 1796

Bill 119 HR 1796, also known as the Sickle Cell Disease Prevention and Treatment Demonstration Program Reauthorization Act, aims to amend the Public Health Service Act in order to reauthorize a program focused on preventing and treating sickle cell disease. Sickle cell disease is a genetic blood disorder that affects red blood cells, causing them to become misshapen and leading to various health complications.

The program in question focuses on demonstrating effective methods for preventing and treating sickle cell disease, with the goal of improving outcomes for individuals living with the condition. By reauthorizing this program, Congress aims to continue supporting research and initiatives aimed at better understanding and addressing sickle cell disease.

This bill is important because sickle cell disease disproportionately affects African Americans and other minority populations, making it a significant public health concern. By reauthorizing this program, Congress is demonstrating its commitment to addressing health disparities and improving outcomes for individuals living with sickle cell disease. Overall, Bill 119 HR 1796 seeks to continue the important work of the Sickle Cell Disease Prevention and Treatment Demonstration Program, with the goal of advancing research, prevention, and treatment efforts related to sickle cell disease.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 1796

Bill HR 1796 is currently in the status of Bill Introduced since March 3, 2025. Bill HR 1796 was introduced during Congress 119 and was introduced to the House on March 3, 2025. Bill HR 1796's most recent activity was Referred to the House Committee on Energy and Commerce. as of March 3, 2025

Bipartisan Support of Bill HR 1796

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 1796

Primary Policy Focus

Health

Alternate Title(s) of Bill HR 1796

To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program.

Comments

Matthias Buckley

1,157

1 year ago

I don't think this bill is a good idea. It's just a waste of money and resources. Why should we be spending money on something like this when there are so many other important issues that need to be addressed? Who even benefits from this bill anyway?